ZNTL
Zentalis Pharmaceuticals, Inc.Company with tickers: ZNTL
CIK
1725160
CUSIP
98943L107
Shares Outstanding
71,186,348
Website
https://www.zentalis.com
Investor Relations
https://ir.zentalis.com/overview/default.aspx
13F Activity (30d)
9 filings
8 filers
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Shannon Campbell | Class I director | Appointed | 2026-05-27 |